Given China’s status as the world’s second most populous nation and an economic powerhouse, the country represents both a monumental market opportunity and a dynamic arena of challenges for pharmaceutical products. With its rapidly evolving healthcare system, limited transparency of public information, and language barriers, China has never been an easy market for overseas pharmaceutical companies to enter.
Our market access experts have outlined the healthcare system and key market access pathways that are opening in China for pharmaceutical products, including vaccines. In this article, our team delves into the current trends and challenges that pharma companies need to consider when devising successful market access strategies for this unique market.
Learn more from the article “Everything You Need to Know About Market Access in China” published on PM360.
Subscribe to our newsletter for the latest news, events, and thought leadership